Navigation Links
Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
Date:11/12/2013

CRANBURY, N.J., Nov. 12, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that the United States Patent and Trademark Office today issued two new patents to Palatin.  Both patents support Palatin's program developing synthetic mimetics of the neuropeptide hormone atrial natriuretic peptide. These mimetics may be useful in treatment of acute asthma, other pulmonary diseases, heart failure, hypertension and other indications.

U.S. Patent 8,580,747, entitled "Cyclic Natriuretic Peptide Constructs," has composition of matter claims relating to Palatin's PL-3994 natriuretic peptide receptor-A agonist for treatment of cardiovascular and pulmonary indications.  PL-3994 has completed two early stage human clinical studies, a Phase 1 trial in healthy volunteers and a Phase 2A trial in volunteers with controlled hypertension.

U.S. Patent 8,580,746, entitled "Amide Linkage Cyclic Natriuretic Peptide Constructs," has composition of matter claims to a novel series of mimetics of atrial natriuretic peptide.  These compounds have potential utility in a number of cardiovascular and pulmonary indications.

"We are pleased to have two new issued patents supporting our natriuretic peptide portfolio.  Our mimetic peptides have a much longer half-life than endogenous atrial natriuretic peptide, giving them important drug-like properties," stated Carl Spana, Ph.D., President and CEO of Palatin.

The issued patents have a twenty-year term that will not expire until March 2027.

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with sign
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
3. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
5. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
6. Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
7. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
8. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
9. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
10. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
11. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Pete Rose, baseball,s all-time hits leader, is the ... reliever Myoflex, Ducere Pharma has announced. "Pete,s a ... to have him on board with Myoflex," said Ducere Pharma ... legendary player who is known across all generations. The passion ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... the World Health Organization warned that a Swine Flu ... firm announced it will host a teleconference for insurance ... seen with everything from asbestos litigation to hurricanes to ... enormously important role in the global economy when disaster ...
... that new cosmeceutical improves skin barrier function, erythema and ... Senetek PLC (OTC Bulletin Board: SNKTY), a ... that target the science of healthy aging, today announced ... for Improving the Signs and Symptoms of Rosacea," has ...
Cached Medicine Technology:Insurance Industry Teleconference on Swine Flu Pandemic Set for May 13 2Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study 2
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... has released a new blog post explaining the main features ... , Auto insurance quotes help many drivers find the best ... call an agent or visit an agency for price information. ... http://autocarinsurancebest.com/ . , Every business who relies heavily on ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 JJsHouse.com is a ... dresses. Today, the business announces its latest collection of ... , “The most important issue is the wedding dress on ... thing in a woman’s life. Every bride wants to find ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... Texas, Nov. 7 Perot Systems,Corporation (NYSE: ... a company it acquired in August 2007, will ... important milestone toward full,integration. Perot Systems will now ... which reflects its ability to access the global ...
... announced today that Immediate Past President and public,health leader ... home outside,East Lansing, Michigan. He was diagnosed with pancreatic ... served as the 162nd,president of the AMA from June ... on,preventive medicine and had been a longtime public health ...
... whose nose has been destroyed by a tumor or injury ... among the most challenging tasks in plastic surgery. Helmut Fischer ... surgery in the current issue of Deutsches rzteblatt International ... authors present the case of a woman who had had ...
... A unique approach to bone marrow transplantation pioneered in ... physician has proven to be the only safe and ... new study. , Lakshmanan Krishnamurti, MD, a pediatric hematologist/oncologist ... marrow transplantation which relies on reduced-intensity conditioning (RIC). RIC ...
... Healthcare,Solutions, Inc. (formerly named Allscripts Healthcare Solutions, Inc.), ... and,headquartered in Chicago, Illinois announced today its offer ... Senior Debentures due 2024 (the,"Debentures") at a purchase ... 100% of the principal amount of the Debentures ...
... 700 health plans evaluated based on quality of ... U.S. News Media Group and The,National Committee for ... of America,s Best Health Plans on USNews.com. Launched ... Americans prepare to,select their healthcare coverage, the 2008 ...
Cached Medicine News:Health News:Perot Systems Announces Name Change of JJWild 2Health News:Perot Systems Announces Name Change of JJWild 3Health News:AMA Immediate Past President Ron Davis Loses Battle With Cancer, Leaves Enduring AMA and Public Health Legacy 2Health News:AMA Immediate Past President Ron Davis Loses Battle With Cancer, Leaves Enduring AMA and Public Health Legacy 3Health News:Children's Hospital study demonstrates how bone marrow transplant can cure sickle cell disease 2Health News:Allscripts Announces Notice of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 2Health News:Allscripts Announces Notice of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 3Health News:Allscripts Announces Notice of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024 4Health News:U.S. News Media Group and NCQA Release 2008 Rankings for America's Best Health Plans 2Health News:U.S. News Media Group and NCQA Release 2008 Rankings for America's Best Health Plans 3
Headlight module is mounted on UltraLite Plus sweatband....
The ICP-Monitor for intraventricular, intraparenchymal and epidural measurement of intracranial pressure and for measuring cerebral perfusion pressure and compliance....
It is a fiberoptic based intracranial monitoring systems for continuous monitoring of pressure....
... ICP Monitoring System provides ... intracranial pressure at the ... levels. The information is ... through a hydrostatic column ...
Medicine Products: